AST-203 / Aptamer Sci, Kolon Life Sci - LARVOL DELTA

Profound Hepatocellular Liver Injury in a 26-Year-Old With Concomitant Intrahepatic Cholestasis of Pregnancy (ICP): A Diagnostic Conundrum (ACG 2026) - "Course complicated by worsening LFTs (AST 203/ALT 489â AST 2,244 /ALT 2,725/ALP 175), impaired synthetic function (INR 1.5, albumin 2.7, T bilirubin 2.3) & BA elevation (99 µmol/L)...Given concerns for overlapping drug-induced liver injury (DILI) & intrahepatic cholestasis of pregnancy (ICP), ursodeoxycholic acid & N-acetylcysteine (NAC) were started...Amoxicillin-clavulanate is the most common cause of idiosyncratic DILI in the US and accounts for 11% of cases...D. Portal tracts showing no significant inflammation; favoring a non-infectious etiology"

Autoimmune Hepatitis • Cholestasis • Genetic Disorders • Gynecology • Hepatology • Immunology • Inflammation • Liver Failure • Urticaria • ABCB1

Tick-Borne Double Trouble: Co-Infection of Babesiosis and Anaplasmosis (ACG 2026) - "Case Description/ A 96-year-old woman with a medical history of hyperlipidemia and DVT on apixaban first presented with lethargy and was found to have babesiosis...She was started on atovaquone and azithromycin and discharged home...Over the next two days, her liver enzymes rose to ALT 553, AST 203, ALP 730, and total bilirubin 2.7...She was empirically started on doxycycline given the likelihood of co-infection with Lyme disease...This emphasizes the importance of recognition of both typical and atypical presentations of these infections, and if initial treatment fails, consideration of co-infection. Co-infection complicates disease courses by possibly increasing disease severity, risk of adverse effects, and further convoluting management."

Cardiovascular • Dyslipidemia • Hematological Disorders • Hepatology • Infectious Disease • Inflammatory Arthritis • Liver Failure • Lyme Disease • Pancreatitis

AST-203, a novel Trop2-targeting aptamer-drug conjugate, exhibits potent antitumor efficacy for the treatment of solid tumors (AACR 2025) - "Trodelvy, a Trop2-targeting antibody-drug conjugate (ADC) linked to the topoisomerase I inhibitor SN-38, has been approved for the treatment of triple-negative breast cancer. AST-203 shows the potential of a promising next-generation therapeutic for Trop2-positive solid tumors. Its superior efficacy and safety compared to traditional antibody-drug conjugates highlight its potential to improve therapeutic outcomes for Trop2-expressing cancers. These findings underscore AST-203 as a significant advancement in aptamer-based therapeutics."

Clinical • Biliary Cancer • Breast Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer • TACSTD2

Aptamer Science and Kolon Pharmaceutical, TROP2 Target Joint Research MOU [Google translation] (Hankyung) - "Aptamer Science announced on the 15th that it signed a memorandum of understanding (MOU) with Kolon Pharmaceutical for joint research and development of 'AST-203', a new pancreatic cancer drug candidate. Through this agreement, the two companies will conduct research and development cooperation to develop AST-203 as a pancreatic cancer treatment and move forward with business cooperation for global technology transfer (license-out)."

Commercial • Oncology • Pancreatic Cancer